Citius Pharmaceuticals, Inc.
CTXRHealthcare|Biotechnology|US
$0.55
-0.01 (-2.21%)
DCF Value
$0.92
Cash / Share
$0.65
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT01871727 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma | Persistent or Recurrent Cutaneous T-Cell Lymphoma | P3 | Completed | 112 | Open-label | E7777 9 mcg/kg |
| NCT05348200 Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids | Hemorrhoids | P2 | Completed | 304 | RCT, Double-blind | Monad 1, Monad 2, Monad 3, Combination - CITI-002 (low dose), Combination - CITI-002 (high dose) |
| NCT02689856 Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids | Hemorrhoids | P2 | Completed | 211 | RCT, Double-blind | Hydrocortisone acetate and lidocaine hydrochloride, Placebo control, Hydrocortisone acetate, Lidocaine hydrochloride |